Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Vitamin D Levels Associated With Fatigue, Musculoskeletal Pain In Patients With Fibromyalgia

Sunday 19 July 2015


From Fibromyalgia News Today:


Vitamin D

Vitamin D Levels Associated With Fatigue, Musculoskeletal Pain in Patients With Fibromyalgia

By Teresa Pais, PhD
July 15th, 2015

Researchers from Seoul presented study results on vitamin D deficiency in patients with rheumatic diseases at the European League Against Rheumatism Annual European Congress of Rheumatology (EULAR) in Rome, June 10-13. The poster entitled: “Vitamin D status and the efficacy of high-dose intramuscular cholecalciferol on musculoskeletal pain and morning fatigue in patients with chronic rheumatic diseases” was presented during the session “Fibromyalgia and pain in rheumatic diseases”.

Low levels of vitamin D have been reported in patients with inflammatory rheumatic conditions such as rheumatoid arthritis (RA), osteoarthritis (OA) and fibromyalgia syndrome (FMS). Vitamin D is acquired either from dietary sources of from exposure to ultraviolet B (UVB) radiation, which converts the precursors in the skin into cholecalciferol. In the liver, Vitamin D and cholecalciferol are converted to 25-hydroxyvitamin D (25-OHD), allowing to measure the status of Vitamin D in the organism.

In this study researchers determined the association between serum 25-OHD and musculoskeletal pain or morning fatigue in RA, OA and FMS patients. They found that 77.5% of patients with FM had significantly lower levels of vitamin D compared to patients with OA (23.5%) but not to patients with RA (64.4%). They then investigated the efficacy of intramuscular injections of cholecalciferol (every four weeks for three times) to improve the pain and fatigue in those patients with 25-OHD deficiency. They used the Visual analog scale (VAS) to measure musculoskeletal pain and morning fatigue. The patients had to mark on a horizontal line the point that corresponded to their perception of pain and fatigue. Researchers found that VAS for pain and fatigue were significantly decreased in each disease group (RA, OA and FMS) at 12th and 24th weeks after cholecalciferol supplementation and when compared to the score at the beginning of the study (known as “baseline”). The reduction of VAS in FMS patients was lower than those in RA or OA patients. Supplementation with cholecalciferol increased mean serum 25-OHD levels at 12th week (42.5 ± 14.3 ng/mL) compared with baseline (11.3 ± 6.8 ng/mL).

The authors concluded that FMS patients’ lower Vitamin D and serum 25-OHD levels may be associated with musculoskeletal pain and morning fatigue. Intramuscular cholecalciferol supplementation every four weeks significantly increased 25-OHD levels and could reduce pain and fatigue in chronic rheumatic disease patients with vitamin D deficiency.

© BioNews Services 2015. All rights reserved.


The above originally appeared here.


Arrow right

More Fibromyalgia News



blog comments powered by Disqus
Previous Previous Page